

Paris Saint-Germain Adopts Japanese Hydrogen Inhalation Device “Sulive”

Introduced as a New Recovery Solution for Professional Athletes

SUIISO JAPAN Co., Ltd. December 24, 2025 | 10:26 AM JST



Paris Saint-Germain, One of France's Most Prestigious Football Clubs

SUIISO JAPAN Co., Ltd. —Osaka, Japan (CEO: Yo Inaishi) is pleased to announce that the world-renowned French football club **Paris Saint-Germain (PSG)** has officially introduced the Japanese-made hydrogen inhalation device “**Sulive**” into its medical and conditioning programs.


Paris Saint-Germain is one of Europe's leading football clubs, consistently competing at the highest international level. The club continuously seeks advanced recovery and conditioning solutions to support player performance, and as part of this initiative, has selected Sulive as a new recovery tool.

The following two models have been implemented by PSG:

- **Sulive SS-300+** (Aug, 2023)
- **Sulive SS-700M** (Aug, 2025)

These devices are primarily utilized under the supervision of the club's medical team, with the aim of supporting post-training recovery and physical conditioning.


Why Suilive Was Selected



Japanese Manufacturing Quality

Suilive is entirely developed and manufactured in Japan, including its core electrolyzer.

Through integrated production and Japanese craftsmanship, the system delivers stable output, durability, and long-term reliability.



Long-Term Upgrade System

Suilive features a proprietary upgrade system that allows performance improvements and functional enhancements over time.

This approach enables long-term use while reducing unnecessary replacement, contributing to both sustainability and cost efficiency.



Medical Supervision & Research

Suilive is supported by seven supervising physicians from different medical specialties, who continuously evaluate safety and performance from a clinical perspective.

In addition, one supervising physician published an international academic paper on hydrogen and the nervous system in 2025, with further research publications planned for 2026.

This ongoing medical validation framework was a key factor in PSG's decision to adopt the technology.

Global Expansion



As of **December 2025**, SUIISO JAPAN products have been introduced in **24 countries worldwide**.

The company has also presented hydrogen therapy concepts to more than **300 physicians across Eurasia**, strengthening international awareness and trust in Japanese hydrogen technology.

Message from the CEO

“We are deeply honored that Paris Saint-Germain has chosen Suilive.

We sincerely thank everyone who supported this project.

At SUIISO JAPAN, we remain committed to delivering safe, reliable, and high-quality products that contribute to health worldwide. We will continue to challenge ourselves and pursue innovation without compromise.”

— Yo Inaishi, CEO, SUIISO JAPAN Co., Ltd.

Company Profile

Company Name: SUIISO JAPAN Co., Ltd.

Representative: Yo Inaishi, President & CEO

Head Office: Takatsuki City, Osaka, Japan

Business Activities: Research, development, manufacturing, and sales of hydrogen inhalation devices, electrolyzers, and hydrogen dissolution systems; promotion of hydrogen agriculture projects

Brand: Suilive

Website: <https://suilive-suisojapan.com>